Objective: To evaluate the clinical use of a self-ligating loop (SLL) for partial or complete liver lobectomy in a variety of companion animal species.
Design: Retrospective case series.
Animals: 22 dogs, 2 cats, 4 rabbits, and 1 ferret with partial or complete liver lobectomy performed with an SLL.
Procedures: Medical records of companion animal patients that underwent partial or complete liver lobectomy with an SLL between 2009 and 2012 at the Angell Animal Medical Center were reviewed, and signalment, intraoperative and postoperative complications, histologic diagnosis, hospital discharge (yes or no), time to hospital discharge, and short-term survival rate were recorded. Follow-up information was obtained through evaluation of medical records.
Results: 28 of 29 (97%) patients were discharged from the hospital and survived at least 5 days after discharge. Of the 29 patients, 3 underwent 2 liver lobectomies. During 4 of 32 (12.5%) lobectomies, mild intraoperative bleeding occurred on the cut surface of the liver after transection. No transection performed with ≥ 2 SLLs resulted in notable intraoperative bleeding. One of 29 (3.4%) patients had evidence of postoperative hemoabdomen, which was successfully treated with a single packed RBC transfusion. Expansion of the SLL diameter from 8 to 15 cm was accomplished to allow for resection of larger masses.
Conclusions And Clinical Relevance: Use of an SLL for partial or complete liver lobectomy in a variety of companion animal species was a safe technique and was associated with low morbidity and mortality rates. Expansion of the ligature loop diameter and use of multiple SLLs may be necessary for larger lobectomies.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.2460/javma.244.6.693 | DOI Listing |
Psychol Serv
January 2025
Department of Psychiatry, University of Colorado-Anschutz Medical Campus.
Partial hospitalization programs (PHPs) are increasingly relied upon to provide intensive mental health treatment for youth with acute and severely impairing mental health symptoms, yet very few interventions have been adapted to fit this unique delivery context. Transdiagnostic treatments hold promise for addressing the complex clinical presentations and workflow needs of PHP programs, but more work is needed to understand factors that influence successful implementation. We conducted a formative implementation process evaluation to identify barriers and facilitators of acceptability, appropriateness, and feasibility of implementing an evidence-based transdiagnostic intervention in a PHP setting and further targets for intervention and implementation adaptation.
View Article and Find Full Text PDFPLoS Pathog
January 2025
Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, United Kingdom.
Whipworms (Trichuris spp) are ubiquitous parasites of humans and domestic and wild mammals that cause chronic disease, considerably impacting human and animal health. Egg hatching is a critical phase in the whipworm life cycle that marks the initiation of infection, with newly hatched larvae rapidly migrating to and invading host intestinal epithelial cells. Hatching is triggered by the host microbiota; however, the physical and chemical interactions between bacteria and whipworm eggs, as well as the bacterial and larval responses that result in the disintegration of the polar plug and larval eclosion, are not completely understood.
View Article and Find Full Text PDFCurr Opin Oncol
December 2024
Université Libre de Bruxelles, Hôpital Universitaire de Bruxelles, Instiut Jules Bordet, Departement of Medical Oncology.
Purpose Of Review: This review evaluates by analyzing recent studies whether pathological complete response (pCR) can be used as a reliable surrogate marker for overall survival (OS) in melanoma treated with neoadjuvant immunotherapy.
Recent Findings: Trials like Neo-Combi, Neo-Trio and COMBI-Neo show that pCR is crucial for long-term success in targeted therapy for melanoma, while studies like OpACIN-neo and SWOG S1801 demonstrate that immunotherapy can provide durable benefits even with partial responses. Findings from NADINA and the INMC analysis highlight that immunotherapy achieves higher pathologic response rates and improved survival outcomes, offering broader benefits compared to the pCR-dependent outcomes of targeted therapy.
Front Oncol
January 2025
Department of Hepatobiliary and Pancreatic Surgery & Retroperitoneal Tumor Surgery, The Affiliated Hospital of Qingdao University, Qingdao, China.
Objective: To evaluate the efficacy and safety of anlotinib combined with envafolimab in the treatment of unresectable or metastatic liposarcoma.
Methods: This single-center, retrospective study enrolled 15 patients with unresectable or metastatic liposarcoma, who were treated at the Retroperitoneal Tumor Surgery Research Center of Qingdao University Affiliated Hospital between April 2022 and November 2023. The treatment regimen consisted of anlotinib combined with envafolimab.
Front Oncol
January 2025
State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
Objective: The current clinical data regarding the re-administration of PARPi maintenance therapy in platinum sensitive recurrent ovarian cancer (PSROC) is limited. This study aims to investigate the efficacy and associated factors of PARPi re-maintenance therapy in PSROC patients in China.
Methods: In this study, there were 201 patients with PSROC who had received maintenance therapy previously and achieved complete or partial response after platinum-based chemotherapy upon recurrence.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!